logo
Twitter
Discord
Email
logo
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

NASDAQ•DAWN
CEO: Dr. Jeremy Bender M.B.A., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-05-27
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Contact Information
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, 94005, United States
650-484-0899
dayonebio.com
Market Cap
$1.04B
P/E (TTM)
-6.9
38.2
Dividend Yield
--
52W High
$13.53
52W Low
$5.64
52W Range
57%
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$39.80M-57.56%
4-Quarter Trend

EPS

-$0.19-150.00%
4-Quarter Trend

FCF

-$5.81M+16.78%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

OJEMDA US Product Sales Net product revenue reached $102.6M for nine months, surging 263.0% due to successful US commercial launch of OJEMDA.
Operations Loss Significantly Reduced Loss from operations improved 34.0% to $100.3M for nine months, driven by lower R&D spending post-milestone payments.
R&D Expenses Decrease Nine-month R&D expenses fell 35.4% to $107.2M, reflecting reduced license payments and winding down VRK1 program.
Cash Reserves Decline Cash and equivalents decreased to $43.3M as of September 30, 2025, down from $125.0M at year-end 2024.

Risk Factors

Revenue Highly Customer Concentrated Nine-month product revenue heavily reliant on two customers, accounting for 98.3% of total net product revenue.
Expecting Continued Operating Losses Incurred $86.0M net loss for nine months; expects continued losses for foreseeable future, requiring additional capital.
Clinical Trial Outcomes Uncertain Future success depends on favorable results in ongoing pivotal Phase 3 FIREFLY-2 trial; failure risks reputation and business.
Intellectual Property Litigation Risk Reliance on licensed IP means disputes or challenges could impair rights, leading to costly litigation and business harm.

Outlook

Advance Tovorafenib Pipeline Trials Continue FIREFLY-2 Phase 3 trial enrollment for front-line pLGG; DAY301 Phase 1a/b trial ongoing.
Need Additional Financing Current liquidity sufficient for twelve months; anticipates needing additional capital to fund planned clinical development programs.
Maximize Ipsen Commercialization Future revenue tied to successful ex-US commercialization by Ipsen, including milestone payments and tiered royalties.
Retain Key Scientific Personnel Focus on retaining executive officers and key employees amid fierce competition in the San Francisco Bay Area talent pool.

Peer Comparison

Revenue (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Akebia Therapeutics, Inc.AKBA
$225.07M
+32.5%
Geron CorporationGERN
$183.40M
+522.1%

Gross Margin (Latest Quarter)

Arvinas, Inc.ARVN
100.0%
+0.0pp
Day One Biopharmaceuticals, Inc.DAWN
88.7%
-9.6pp
UroGen Pharma Ltd.URGN
88.1%
-2.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TERN$3.30B-35.5-30.0%0.3%
ERAS$2.73B-21.4-33.1%11.5%
OLMA$2.13B-15.5-41.5%1.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
10.9%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 24, 2026
|
EPS:-$0.18
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $39.80M-57.6%
    |
    EPS: $-0.19-150.0%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $33.91M+313.9%
    |
    EPS: $-0.29+473.1%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $30.76M+0.0%
    |
    EPS: $-0.35-51.4%
    Beat

  • Form 10-K/A - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 6, 2025|
    Revenue: $131.16M+0.0%
    |
    EPS: $-1.02+57.0%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 25, 2025|Refer to amended data

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 30, 2024|
    Revenue: $93.76M+0.0%
    |
    EPS: $0.38-170.4%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 2, 2024|
    Revenue: $8.19M+0.0%
    |
    EPS: $-0.05-91.7%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 6, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.72+46.9%
    N/A